slx-2101

SLx-2101 is an oral, potent, selective, fast-onset, long-acting phosphodiesterase type 5 (PDE5) inhibitor. It was developed to expand the therapeutic potential of PDE5 inhibition beyond erectile dysfunction into larger cardiovascular markets such as hypertension and Raynaud’s disease. Compared to currently marketed PDE5 inhibitors, SLx-2101 preferentially distributes into cardiovascular tissue and achieves sustained plasma levels with a long duration of action (up to 48 hours), without accumulation upon repeat dosing. Clinical trials have demonstrated its safety and tolerability in early pharmacokinetic studies for both erectile dysfunction and hypertension[1][2][3][4][5][8].